secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biofrontera Inc. (BFRI)
CIK:        0001858685
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001641172-25-023598
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biofrontera Q2 rev $9.0M (+15%); net loss $5.3M; restructures AG deal, new royalty 12-15%
--------------------------------------------------------------------------------

- Q2 2025 revenue $9.0M (up 15% YoY); net loss $5.3M vs $0.3M in Q2 2024.
- Adjusted EBITDA negative $5.1M vs negative $4.7M; cash $7.2M at June 30.
- Acquired US IP and NDA from Biofrontera AG; new Ameluz royalty 12%/15% vs prior 25-35%.
- Received $11M additional funding; US patent for revised Ameluz granted through 2043.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858685/000164117225023598/0001641172-25-023598-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858685/000164117225023598/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-023598

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer